Bone Abstracts

Recombinant human parathyroid hormone (rhPTH) (1–84) is currently being developed as PTH replacement therapy for patients with hypoparathyroidism. Because rhPTH(1–84) is administered subcutaneously, we compared the pharmacokinetic profile of PTH(1–84) and the calcemic response following S.C. rhPTH(1–84) injection in thigh and abdomen.In this phase 1, open-label, three-way crossover study, healthy postmenopausal women received three ra...

Patients with hypoparathyroidism lack sufficient parathyroid hormone (PTH) and exhibit reduced bone turnover, abnormally increased bone mineral density (BMD), and abnormal bone microarchitecture. Current treatment regimens fail to address underlying PTH deficiency. In the REPLACE phase III trial, treatment with rhPTH(1–84) restored mineral homeostasis, increased bone turnover markers (BTMs), and decreased BMD in patients with hypoparathyroidism.REPE...

see PP92....

Hypoparathyroidism results in low bone turnover and increased bone mineral density (BMD). Replacing deficient PTH with rhPTH(1–84) has the potential to correct these skeletal abnormalities. To investigate the effect of rhPTH(1–84) on BMD and bone turnover markers (BTMs), data from two studies were assessed.REPLACE, a double-blind, multicenter, placebo-controlled study, randomized 134 patients with hypoparathyroidism to receive once-daily rhPTH(...